Education
About Us
Working with TipRanks
Follow Us
GlucoTrack (GCTK)
NASDAQ:GCTK
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$1.31 - $30.52
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$1.53M
Enterprise Value-$6.97M
Total Cash (Recent Filing)$7.87M
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Apr 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding1,011,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-12.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.22
Enterprise Value/Market Cap-4.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit166.00
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened IP PortfolioThe issuance of three patents for the continuous blood glucose monitoring platform creates durable barriers to entry around sensor chemistry, intravascular lead design and low-power electronics. This strengthens bargaining power with partners and defends commercialization efforts over the coming quarters.
Differentiated Implantable CBGM StrategyA multi‑year, fully implantable CBGM targets an unmet need vs short-lived subcutaneous sensors, offering a structurally differentiated product proposition. If clinical progress continues, this product strategy supports durable market opportunity and long-term adoption potential in diabetes care.
Near-term Liquidity ImprovementThe $4.0M private placement, with lock-ups, exercise caps and registration commitments, provides runway for ongoing clinical and development activities. The financing also constrains dilution pathways temporarily, reducing immediate solvency pressure and enabling execution over the next several months.
Bears Say
No Meaningful Revenue BaseSustained lack of revenue indicates the business has not achieved commercial traction. Without recurring sales, the company depends on funding to advance trials and commercialization, increasing execution and commercialization risk across a multi‑quarter horizon until meaningful revenue is established.
Severe And Growing Cash BurnMaterial negative operating and free cash flow that has worsened to ~-$12.5M annually signals heavy funding needs. Persistent cash burn without revenues implies repeated capital raises, dilutive financing, and heightened execution risk for sustaining clinical programs over the next several quarters.
Negative Equity And Solvency RiskA sharp shift to materially negative equity reflects accumulated losses and weak capitalization. Even with low absolute debt, negative equity constrains financing options, raises the cost of capital and increases the risk of funding stress or restructuring during the next few quarters if operational progress stalls.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $1.31 and its highest was $30.52 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $1.53M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Apr 06, 2026 which is in 28 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on Nov 13, 2025. The company reported -$4.638 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.638.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 1,011,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$4.638 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.642%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.